Shanghai Junshi Bio
Launch date
Employees
Market cap
€2.6b
Enterprise valuation
€2.4b (Public information from Sep 2024)
Share price
HKD10.64 1877.HK
Shanghai Shanghai (HQ)
Financials
Estimates*
| CNY | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 1.6b | 4.0b | 1.5b | 1.5b | 1.8b | 2.4b | 3.0b |
| % growth | 106 % | 152 % | (64 %) | 3 % | 17 % | 38 % | 22 % |
| EBITDA | (1.5b) | (423m) | (2.4b) | (2.1b) | (1.5b) | (1.2b) | (838m) |
| % EBITDA margin | (96 %) | (11 %) | (164 %) | (143 %) | (87 %) | (51 %) | (28 %) |
| Profit | (1.7b) | (719m) | (2.4b) | (2.3b) | (1.5b) | (718m) | (1.0b) |
| % profit margin | (104 %) | (18 %) | (164 %) | (152 %) | (84 %) | (29 %) | (34 %) |
| EV / revenue | 39.0x | 13.3x | 36.1x | 22.5x | 11.1x | 8.3x | 7.0x |
| EV / EBITDA | -40.7x | -127.0x | -22.1x | -15.8x | -12.8x | -16.3x | -24.7x |
| R&D budget | 1.8b | 2.1b | 2.4b | 1.9b | - | - | - |
| R&D % of revenue | 111 % | 51 % | 164 % | 129 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
N/A | Early VC | ||
| N/A | €394m | IPO | |
| N/A | $692m | IPO | |
| Total Funding | - | ||
